Fertility and Sterility
Volume 87, Issue 6 , Pages 1377-1382 , June 2007

Investigation of hypothalamo-pituitary-gonadal axis and glucose intolerance among the first-degree female relatives of women with polycystic ovary syndrome

Presented in part at the European Congress of Endocrinology, Göteborg, Sweden, September 3–7, 2005.

  • Kürşad Ünlühızarcı

      Affiliations

    • Department of Endocrinology Erciyes University Medical School, Kayseri, Turkey
    • ,
  • Mehtap Özocak

      Affiliations

    • Department of Endocrinology Erciyes University Medical School, Kayseri, Turkey
    • ,
  • Fatih Tanrıverdi

      Affiliations

    • Department of Endocrinology Erciyes University Medical School, Kayseri, Turkey
    • ,
  • Hulusi Atmaca

      Affiliations

    • Department of Endocrinology Karaelmas University Medical School, Zonguldak, Turkey
    • ,
  • Fahrettin Keleştimur

      Affiliations

    • Department of Endocrinology Erciyes University Medical School, Kayseri, Turkey
    • Corresponding Author InformationReprint requests: Prof. Dr. Fahrettin Keleştimur, Department of Endocrinology, Erciyes University Medical School, Kayseri, Turkey (FAX: + 90 352 437 58 07).

Received 19 June 2006 ,Revised 18 October 2006 ,Accepted 15 November 2006.

References 

  1. Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril. 2002;77:1091–1105
  2. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91:41–53
  3. Caballero AE. Metabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situation. Arch Med Res. 2005;36:241–249
  4. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diab Care. 1999;22:141–146
  5. Unluhizarci K, Colak R, Sahin Y, Bayram F, Keletimur F. The prevalance of glucose intolerance in women with polycystic ovary syndrome. Turk J Endocrinol Metab. 2000;4:131–137
  6. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90:3231–3242
  7. Legro RS, Driscoll D, Strauss JF, Fox J, Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci U S A. 1998;95:14951–14960
  8. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:11–25
  9. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol. 1981;140:811–830
  10. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and cllassification of diabetes mellitus. Diab Care. 1998;21(Suppl 1):S5–S19
  11. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Diab Care. 2000;23:51–63
  12. Vrbikova J, Bendlova B, Hill M, Vankova M, Vondra K, Starka L. Insulin sensitivity and β cell function in women with polycystic ovary syndrome. Diab Care. 2002;25:1211–1222
  13. Sahin Y, Kelestimur F. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome. Clin Endocrinol. 1993;39:151–155
  14. Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to a dysregulation of androgen secretion. Endocr Rev. 1995;16:321–353
  15. Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson D, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod. 1997;12:2641–2648
  16. Lunde O, Magnus P, Sandvik L, Hoglo S. Familial clustering in polycystic ovary syndrome. Gynecol Obstet Invest. 1989;28:21–30
  17. Sir-Petermann T, Angel B, Maliqueo M, Carvajal F, Santos L, Perez-Bravo F. Prevalence of type 2 diabetes mellitus and insulin resistance in parents of women with polycystic ovary syndrome. Diabetologia. 2002;45:951–964
  18. Norman RJ, Masters S, Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril. 1996;66:941–947
  19. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle (A potential mechanism for insulin resistance in the polycystic ovary syndrome). J Clin Invest. 1995;96:801–810
  20. Yilmaz M, Bukan N, Ersoy R, Karakoc A, Yetkin I, Ayvaz G, et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod. 2005;20:2411–2420
  21. Yildiz BO, Yarali H, Oguz H, Bayraktar M. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:2031–2036
  22. Colila S, Cox NJ, Ehrmann D. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives. J Clin Endocrinol Metab. 2001;86:2021–2031
  23. Baker B, Mandarino L, Brick B, Rizza R, Gerich J. Influence of changes in insulin receptor binding during insulin infusions on the shape of the insulin dose-response curve for glucose disposal in man. J Clin Endocrinol Metab. 1984;58:391–396
  24. Holte J, Bergh T, Berne C, Berglund L, Lithell H. Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1994;78:1051–1058
  25. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:2581–2593
  26. Kashar-Miller MD, Nixon C, Boots LR, Go RC, Azziz R. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75:51–58
  27. Ibanez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GNRH agonist and human chorionic gonadotropin stimulating testing. J Clin Endocrinol Metab. 1996;81:4101–4107
  28. Barnes RB, Rosenfield RL, Burstein S, Ehrmann DA. Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 1989;320:551–565
  29. Suikkari AM, McLachlan V, Montalto J, Calderon I, Healy DL, McLachlan RI. Ultrasonographic appearance of polycystic ovaries is assocaited with exaggerated ovarian androgen and oestradiol responses to gonadotrophin-releasing hormone agonist in women undergoing assisted reproduction treatment. Hum Reprod. 1995;10:511–519
  30. Fulghesu AM, Villa P, Pavone V, Guido M, Apa R, Caruso A, et al. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:641–648
  31. De Leo V, La Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 1999;72:281–285

PII: S0015-0282(06)04565-1

doi: 10.1016/j.fertnstert.2006.11.075

Fertility and Sterility
Volume 87, Issue 6 , Pages 1377-1382 , June 2007

Article Tools